Decoding complex inherited phenotypes in rare disorders: the DECIPHERD initiative for rare undiagnosed diseases in Chile
-
Published:2024-01-04
Issue:
Volume:
Page:
-
ISSN:1018-4813
-
Container-title:European Journal of Human Genetics
-
language:en
-
Short-container-title:Eur J Hum Genet
Author:
Poli M. Cecilia, Rebolledo-Jaramillo BorisORCID, Lagos Catalina, Orellana Joan, Moreno Gabriela, Martín Luz M., Encina GonzaloORCID, Böhme Daniela, Faundes VíctorORCID, Zavala M. JesúsORCID, Hasbún TrinidadORCID, Fischer Sara, Brito Florencia, Araya Diego, Lira Manuel, de la Cruz Javiera, Astudillo Camila, Lay-Son GuillermoORCID, Cares Carolina, Aracena Mariana, Martin Esteban San, Coban-Akdemir Zeynep, Posey Jennifer E.ORCID, Lupski James R.ORCID, Repetto Gabriela M.ORCID
Abstract
AbstractRare diseases affect millions of people worldwide, and most have a genetic etiology. The incorporation of next-generation sequencing into clinical settings, particularly exome and genome sequencing, has resulted in an unprecedented improvement in diagnosis and discovery in the past decade. Nevertheless, these tools are unavailable in many countries, increasing health care gaps between high- and low-and-middle-income countries and prolonging the “diagnostic odyssey” for patients. To advance genomic diagnoses in a setting of limited genomic resources, we developed DECIPHERD, an undiagnosed diseases program in Chile. DECIPHERD was implemented in two phases: training and local development. The training phase relied on international collaboration with Baylor College of Medicine, and the local development was structured as a hybrid model, where clinical and bioinformatics analysis were performed in-house and sequencing outsourced abroad, due to lack of high-throughput equipment in Chile. We describe the implementation process and findings of the first 103 patients. They had heterogeneous phenotypes, including congenital anomalies, intellectual disabilities and/or immune system dysfunction. Patients underwent clinical exome or research exome sequencing, as solo cases or with parents using a trio design. We identified pathogenic, likely pathogenic or variants of unknown significance in genes related to the patients´ phenotypes in 47 (45.6%) of them. Half were de novo informative variants, and half of the identified variants have not been previously reported in public databases. DECIPHERD ended the diagnostic odyssey for many participants. This hybrid strategy may be useful for settings of similarly limited genomic resources and lead to discoveries in understudied populations.
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Genetics
Reference38 articles.
1. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165–73. 2. World Bank. Population, Total and Low and Middle Income Countries. 2021. https://data.worldbank.org/indicator/SP.POP.TOTL?locations=XO&name_desc=false. 3. Dharssi S, Wong-Rieger D, Harold M, Terry S. Review of 11 national policies for rare diseases in the context of key patient needs. Orphanet J Rare Dis. 2017;12:63. Mar 31. 4. Boycott KM, Rath A, Chong JX, Hartley T, Alkuraya FS, Baynam G, et al. International cooperation to enable the diagnosis of all rare genetic diseases. Am J Hum Genet. 2017;100:695–705. 5. Malinowski J, Miller DT, Demmer L, Gannon J, Pereira EM, Schroeder MC, et al. Systematic evidence-based review: outcomes from exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability. Genet Med. 2020;22:986–1004.
|
|